期刊文献+

他汀类药物引起骨骼肌相关不良反应的临床特点及文献复习

Clinical characteristics and literature review of skeletal muscle related adverse drug reactions cansed by statins
下载PDF
导出
摘要 目的探讨他汀类药物引起骨骼肌相关不良反应的临床特点。方法结合文献回顾性分析1例服用他汀类药物后发生骨骼肌相关不良反应疗养员的临床特点。结果他汀类药物引起骨骼肌相关不良反应主要表现为肌肉疼痛、无力伴(或)有肌酶升高。高龄、长期服用、大剂量服用的患者发生率更高。本例患者服用他汀类药物过程中出现骨骼肌损害,但仅表现为肌酸磷酸激酶升高,停药后肌酸激酶逐渐降低。结论他汀类药物引起骨骼肌相关不良反应临床罕见,其临床表现多样。在使用过程中应密切关注,减少相关不良反应发生。 Objective To analyze the clinical characteristics of skeletal muscle related adverse drug reactions caused by statins. Methods The clinical characteristics of one convalescent with skeletal muscle related adverse drug reactions caused by statins was retrospectively analyzed together with literature review. Results The main clinical manifestations of skeletal muscle related adverse reactions caused by statins were myalgia and muscle weakness with creatase rise.And the occurrence rate was high in people with advanced age,long-term medication,and large dose medication.This sufferer showed skeletal muscle injury during the medication of statins but only in creatine phosphokinase rise,and creatine kinase gradually decreased with drug withdrawal. Conclusion Skeletal muscle related adverse drug reactions caused by statins are clinically rare but with various clinical manifestations,which should be closely watched in use so as to reduce the occurrence of adverse reactions.
作者 赵光 贾静怡
出处 《中国疗养医学》 2015年第3期328-329,共2页 Chinese Journal of Convalescent Medicine
关键词 他汀类药物 骨骼肌 不良反应 Statins Skeletal muscle Adverse reactions
  • 相关文献

参考文献3

二级参考文献46

  • 1严志琼,徐文哲.横纹肌溶解症的病因探讨[J].中国中西医结合肾病杂志,2006,7(5):308-310. 被引量:24
  • 2刘殿强,蔡青,周珍.横纹肌溶解症致急性肾衰竭19例临床分析[J].实用全科医学,2006,4(4):432-433. 被引量:9
  • 3Schreiber D H, Anderson T R. Statin-induced rhabdomyolysis[J]. J Emerg Med, 2006, 31 (2): 177-180.
  • 4Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins-mechanisms and consequences[J]. Cur Drug Saf, 2009, 4(3): 209-228.
  • 5Thompson P D, Clarson P, Karas R H. Statin-associated myopathy[J]. JAm MedAssoc, 2003, 289: 1681-1690.
  • 6Bays H. Statin Safety: An overview and assessment of the data-2005[J]. Ame J Cardiol, 2006, 97(8a): 6c-26c.
  • 7Vaklavas C, Chatzisis Y S, Ziakas A, et al. Molecular basis of statin-associated myopathy[J]. Atherosclerosis, 2009; 202: 18-28.
  • 8Marcoff L, Thompson P D. The role of coenzyme Q10 in statin-associated myopath[J]. JAm Coll Cardiol, 2007, 49(23): 2231-2237.
  • 9Caso G, Kelly P, Mcnurlan M A, et al. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins[J]. Am JCardiol, 2007, 99: 1409-1412.
  • 10Nishimoto T, Tozawa R, Amano Y, et al. Comparing myotoxic effects of aqualene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA) reductase inhibitors in human myocytes[J]. Biochem Pharmacol, 2003, 66: 2133-2139.

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部